Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 9, 1998, Pages 1019-1022

  Sasaki, Shigeki ^a   Hashimoto, Tomohiro ^a   Obana, Norihiro ^a   Yasuda, Hideyo ^b   Uehara, Yoshimasa ^c   Maeda, Minoru ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 BIS(INDO 3 YL)MALEIMIDE; ACETYLCYSTEINYL(SERINE)PROLYLLYSYLMETHYL AMIDE; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION;

BINDING SITES; CATALYTIC DOMAIN; CDC2 PROTEIN KINASE; CYCLIN B; DRUG DESIGN; ENZYME INHIBITORS; HISTONES; HUMANS; INDICATORS AND REAGENTS; KINETICS; MODELS, MOLECULAR; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0032080613     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00163-2     Document Type: Article

References (24)

1. 1) L. Meijer and S. H. Kim, Methods in Enzymology, 283:113 (1997), and references cited therein.
2. 2) a) M. Kitagawa, T. Okabe, H. Ogino, H. Matsumoto, I. Suzuki-Takahashi, T. Kokubo, H. Higashi, S. Saitoh, Y. Taya, H. Yasuda, Y. Ohba, S. Nishimura, N. Tanaka, A. Okuyama, Oncogene, 8, 2425 (1993),
3. b) M. Kitagawa, H. Higashi, IS. Takahashi, T. Okabe, H. Ogino, Y. Taya, S. Hishimura, A. Okuyama, Oncogene, 9, 2549 (1994),
4. c) A. Someya, N. Tanaka, A. Okuyama, Biochem. Biophys. Res. Commun., 198, 536 (1994),
5. d) K. Nishio, T. Ishida, H. Arioka, H. Kuiokawa, K. Fukuoka, T. Nomoto, H. Fukumoto, H. Yokote, N. Saijo, Anticancer Research, 16(6B), 3387 (1996).
6. 3) a) G. Kaur, M.Stetler-Stevenson, S. Sehers, P. Worland, H. Sedlacek, C. Myers, J. Czech, R. Naik, E. Sausville, J. Natl. Cancer Inst., 84, 1726 (1992),
7. b) P. J. Worland, G. Kaur, M. Stetler-Stevenson, S. Sebers, O. Sartor, E. A.Sausville, Biochem. Pharmacol., 46, 1831 (1993),
8. c) M.D. Losiewicz, B. A. Carlson, G. Kaur, E. A. Sausville, P. J. Worland, Biochem. Biophys. Res. Commun., 201, 589, (1994).
9. 4) a) U. Schulze-Gahmen, J. Brandsen, H. D. Jones, D. O. Morgan, L. Meijer, J. Vesely, S. H. Kim, Proteins: Struct. Funct. Genet., 22, 378 (1995),
10. b) N. Glab, B. Labidi, LX. Qin, C. Trehin, C. Bergounioux, L. Meijer, FEBS Lett., 353, 207 (1994),
11. b) R. T. Abraham, M. Acquarone, A. Andersen, A. Asensi, R. Belle, F. Berger, C. Bergounioux, G. Brunn, C. Buquet-Fagot, D. Fagot, N. Glab, H. Goudeau, M. Goudeau, P. Guerrier, P. J. Houghton, H. Hendriks, B. Kloareg, M. Lippai, D. Marie, B. Maro, L. Meijer, J. Mester, O. Mulner-Lorillon, S. A. Poulet, E. Schierenberg B. Schutte, D. Vaulot, M. H. Verlhac, Biol. Cell, 83, 105 (1995),
12. c) W. Ongkeko, D. J. Ferguson, A. L. Harris, C. Norbury, J. Cell Sci., 108, 2897 (1995).
13. 5) D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, L. Duhamel, D. Charon, J. Kirilovsky, J. Biol. Chem., 266, 15771 (1991).
14. 6) Reviews: a) S. Moreno, P. Nurse, Cell, 61, 549 (1990),
15. b) H. Yasuda, M. Kamijo, Y. Ohba, Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan) 113, 829 (1993), and references cited therein.
16. 7) A recent example of peptide inhibitors for PKC: T. E. Harris, S. J. Persaud, T. Saermark, P. M. Jones, Mol. Cell. Endocrinol., 121, 133 (1996), and references cited therein.
17. 8) We are grateful to Professor H. Kobayashi, Faculty of Medicine, Kyushu University, Japan, for inhibition assay with use of cdc2 kinase from Xenopus egg extracts.
18. 1H-NMR, and High Resolution FABMS spectra.
19. 2 (10 mM) at pH 7.4. The reaction mixture was passed through a nitrocellulose filter, and the remaining radioactivity of phoshprylated histone on the filter was measured with a liquid scintillation counter.
20. 4.
21. 12) a) H. Fukuzawa, P. M. Li, S. Mizuno, Y. Uehara, Analytical Biochem., 212, 106 (1993),
22. c) P.-M. Li, H.Fukazawa, S. Mizuno, Y. Uehara, Anticancer Res., 13, 1957 (1993),
23. c) Y. Murakami, H. Fukazawa, S. Mizuno, Y. Uehara, Biochem. J., 301, 57 (1994).
24. 13) A successful design of PKC inhibitors connecting multiple structural units with a linker has been recetntly reported, M. Sodeoka, M. A. Arai, K. Adachi, K. Uotsu, and M. Shibasaki, J. Am. Chem. Soc., 120, 457 (1998).